Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC150842-Methoxyestradiol (2-MeOE2)CAS: 362-07-2纯度: >99.50% / >98.00%
2-Methoxyestradiol (2-MeOE2/2-Me)是一种HIF-1α抑制剂。
- GC15104(R)-(+)-Etomoxir sodium saltCAS: 828934-41-4纯度: >99.00%
(R)-(+)-Etomoxir sodium salt(Etomoxir; ETO)是一种用于代谢和心血管疾病的小分子,经酶转化为活性抑制剂乙托莫西里尔辅酶a (IC50 约为0.01-0.70 µM)后,对CPT-1a和CPT-1b的抑制表现出纳摩尔效价。
- GC15134Fludarabine Phosphate (Fludara)CAS: 75607-67-9纯度: >98.00%
A prodrug form of fludarabine and 2-fluoro-ara-ATP
- GC15142PD-1/PD-L1 inhibitor 1 (BMS-1)CAS: 1675201-83-8纯度: >99.50%
PD-1/PD-L1 inhibitor 1 是一种 PD-1/PD-L1 相互作用抑制剂,IC50 值介于 6 和 100 nM . PD-1/PD-L1 调节细胞信号通路和表观遗传修饰,从而抑制 T 细胞和 B 细胞的增殖和效应子功能。
- GC15148Ionomycin calcium saltCAS: 56092-82-1纯度: >98.00%
Ionomycin calcium salt是一种窄谱抗生素,对革兰氏阳性菌具有活性,由丛生链霉菌(Streptomyces conglobatus)产生。
- GC15161Calcium D-PanthotenateCAS: 137-08-6纯度: >98.00% / >99.00%
D-泛酸钙(维生素B5钙盐)是一种维生素,可以降低苹果汁中棒曲霉素的含量。
- GC15168Urolithin ACAS: 1143-70-0纯度: >98.00%
Urolithin A是由鞣花酸和鞣花单宁代谢产生的一种活性成分,可作为酪氨酸酶(IC 50 值为71.44±10.07µmol/L)和单胺氧化酶A(IC 50 值为29.41±9.01µmol/L)的强效抑制剂。
- GC15219ClofarabineCAS: 123318-82-1纯度: >99.50%
A ribonucleotide reductase and DNA polymerase-α inhibitor
- GC15255Decitabine(NSC127716, 5AZA-CdR)CAS: 2353-33-5纯度: >99.50% / >99.00%
地西他滨(Decitabine, DAC)是一种具有口服生物活性的脱氧胞苷类似物抗代谢物,具有DNA甲基转移酶抑制剂的功能。
- GC15272TroglitazoneCAS: 97322-87-7纯度: >98.50% / >98.00% / >96.00%
Troglitazone是一种具有口服活性的过氧化物酶体增殖物激活受体γ(PPARγ)激动剂,对人和鼠的EC 50 值分别为550nM和780nM。
- GC15282LOXO-101 (Larotrectinib) sulfateCAS: 1223405-08-0纯度: >99.50%
LOXO-101 (Larotrectinib) sulfate是一种口服可用的ATP竞争性泛TRK抑制剂,对TRKA和TRKC的IC 50 值分别为0.9nM和2.8nM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC15083 | Celastrol | 34157-83-0 | >99.50% | |
Celastrol是一种蛋白酶体抑制剂,有效且优先的抑制纯化的20S蛋白酶体,IC 50 为2.5 μM。 | ||||
| GC15084 | 2-Methoxyestradiol (2-MeOE2) | 362-07-2 | >99.50% / >98.00% | |
2-Methoxyestradiol (2-MeOE2/2-Me)是一种HIF-1α抑制剂。 | ||||
| GC15089 | Carfilzomib (PR-171) | 868540-17-4 | >99.00% | |
A proteasome inhibitor | ||||
| GC15104 | (R)-(+)-Etomoxir sodium salt | 828934-41-4 | >99.00% | |
(R)-(+)-Etomoxir sodium salt(Etomoxir; ETO)是一种用于代谢和心血管疾病的小分子,经酶转化为活性抑制剂乙托莫西里尔辅酶a (IC50 约为0.01-0.70 µM)后,对CPT-1a和CPT-1b的抑制表现出纳摩尔效价。 | ||||
| GC15134 | Fludarabine Phosphate (Fludara) | 75607-67-9 | >98.00% | |
A prodrug form of fludarabine and 2-fluoro-ara-ATP | ||||
| GC15142 | PD-1/PD-L1 inhibitor 1 (BMS-1) | 1675201-83-8 | >99.50% | |
PD-1/PD-L1 inhibitor 1 是一种 PD-1/PD-L1 相互作用抑制剂,IC50 值介于 6 和 100 nM . PD-1/PD-L1 调节细胞信号通路和表观遗传修饰,从而抑制 T 细胞和 B 细胞的增殖和效应子功能。 | ||||
| GC15148 | Ionomycin calcium salt | 56092-82-1 | >98.00% | |
Ionomycin calcium salt是一种窄谱抗生素,对革兰氏阳性菌具有活性,由丛生链霉菌(Streptomyces conglobatus)产生。 | ||||
| GC15161 | Calcium D-Panthotenate | 137-08-6 | >98.00% / >99.00% | |
D-泛酸钙(维生素B5钙盐)是一种维生素,可以降低苹果汁中棒曲霉素的含量。 | ||||
| GC15164 | PND-1186 | 1061353-68-1 | >99.50% | |
A potent FAK inhibitor | ||||
| GC15166 | Perindopril Erbumine | 107133-36-8 | >99.50% | |
An orally active ACE inhibitor | ||||
| GC15168 | Urolithin A | 1143-70-0 | >98.00% | |
Urolithin A是由鞣花酸和鞣花单宁代谢产生的一种活性成分,可作为酪氨酸酶(IC 50 值为71.44±10.07µmol/L)和单胺氧化酶A(IC 50 值为29.41±9.01µmol/L)的强效抑制剂。 | ||||
| GC15178 | Hexamethonium Bromide | 55-97-0 | >98.00% | |
A nondepolarizing neuromuscular blocking agent | ||||
| GC15211 | Damnacanthal | 477-84-9 | - | |
Damnacanthal 是一种从海巴戟根中分离出来的蒽醌。 | ||||
| GC15219 | Clofarabine | 123318-82-1 | >99.50% | |
A ribonucleotide reductase and DNA polymerase-α inhibitor | ||||
| GC15225 | COTI-2 | 1039455-84-9 | >98.50% | |
An activator of mutant forms of p53 | ||||
| GC15254 | Tandutinib (MLN518) | 387867-13-2 | >99.00% | |
An antagonist of PDGFRβ, FLT3, and c-Kit | ||||
| GC15255 | Decitabine(NSC127716, 5AZA-CdR) | 2353-33-5 | >99.50% / >99.00% | |
地西他滨(Decitabine, DAC)是一种具有口服生物活性的脱氧胞苷类似物抗代谢物,具有DNA甲基转移酶抑制剂的功能。 | ||||
| GC15258 | GN25 | 1227401-27-5 | - | |
Inhibits p53-Snail binding | ||||
| GC15267 | Se-Aspirin | 1850293-95-6 | - | |
A selenium-NSAID hybrid | ||||
| GC15271 | Tyrphostin AG 879 | 148741-30-4 | >99.50% | |
A non-specific tyrphostin ErbB2 inhibitor | ||||
| GC15272 | Troglitazone | 97322-87-7 | >98.50% / >98.00% / >96.00% | |
Troglitazone是一种具有口服活性的过氧化物酶体增殖物激活受体γ(PPARγ)激动剂,对人和鼠的EC 50 值分别为550nM和780nM。 | ||||
| GC15281 | K-252c | 85753-43-1 | >99.00% | |
A cell-permeable PKC inhibitor | ||||
| GC15282 | LOXO-101 (Larotrectinib) sulfate | 1223405-08-0 | >99.50% | |
LOXO-101 (Larotrectinib) sulfate是一种口服可用的ATP竞争性泛TRK抑制剂,对TRKA和TRKC的IC 50 值分别为0.9nM和2.8nM。 | ||||
| GC15291 | GSK3145095 | 1622849-43-7 | >98.00% | |
GSK3145095 是一种 RIP1 激酶抑制剂,IC50 为 6.3 nM。 | ||||
